Allogene Gets Orphan-Drug Tag for T Cell Treatment of Multiple Myeloma

 

• ODD Follows FDA Fast Track Designation Granted for ALLO-605 in Q2 2021
• ALLO-605 is in Phase 1 in the IGNITE Trial and Part of Allogene’s Multi-Pronged Strategy Targeting BCMA
• BCMA Program Clinical Updates are Planned for Late 2022

https://www.biospace.com/article/releases/allogene-therapeutics-receives-fda-orphan-drug-designation-for-allo-605-its-first-turbocar-t-cell-product-candidate-for-the-treatment-of-multiple-myeloma-/